Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study.
OBJECTIVE:To compare incidence of first osteoporotic fracture in two cohorts of postmenopausal women, one treated with bisphosphonates and the other only with calcium and vitamin D. DESIGN:Retrospective population cohort study with paired matching based on data from electronic health records. SETTIN...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4393307?pdf=render |
| _version_ | 1818027194499203072 |
|---|---|
| author | Jordi Real Gisela Galindo Leonardo Galván María Antonia Lafarga María Dolors Rodrigo Marta Ortega |
| author_facet | Jordi Real Gisela Galindo Leonardo Galván María Antonia Lafarga María Dolors Rodrigo Marta Ortega |
| author_sort | Jordi Real |
| collection | DOAJ |
| description | OBJECTIVE:To compare incidence of first osteoporotic fracture in two cohorts of postmenopausal women, one treated with bisphosphonates and the other only with calcium and vitamin D. DESIGN:Retrospective population cohort study with paired matching based on data from electronic health records. SETTING:Women aged 60 years and older in 2005, from 21 primary care centers in a healthcare region of Spain. PARTICIPANTS:Two groups of women aged 60 years and older (n = 1208), prescribed either calcium and vitamin D (CalVitD) or bisphosphonates (BIPHOS) with or without calcium and vitamin D, were compared for the end point of first recorded osteoporotic-related fracture, with 5-years follow-up. MAIN OUTCOME MEASURE:Incidence of first fracture: Vertebral fracture, osteoporosis with pathological fracture, fracture of the upper humeral epiphysis, fracture of the lower radial epiphysis, or femur fracture. RESULTS:Estimated 10-year risk of fracture was 11.4% (95% confidence interval: 9.6 to 13.2), 11.8% (9.2 to 14.3) in the BIPHOS group and 11.1% (8.6 to 13.6) in the CalVitD group. No significant differences were found between groups in total fractures (Hazard ratio = 0.934 (0.67 to 1.31)) or location (vertebral, femoral, radial or humeral). CONCLUSIONS:In postmenopausal women, bisphosphonates have not been shown to better decrease risk of first fracture compared with calcium and vitamin D therapy alone. |
| first_indexed | 2024-12-10T04:44:01Z |
| format | Article |
| id | doaj.art-3daf93f12d9043298d7b4e0e3d595aef |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T04:44:01Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3daf93f12d9043298d7b4e0e3d595aef2022-12-22T02:01:47ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e011817810.1371/journal.pone.0118178Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study.Jordi RealGisela GalindoLeonardo GalvánMaría Antonia LafargaMaría Dolors RodrigoMarta OrtegaOBJECTIVE:To compare incidence of first osteoporotic fracture in two cohorts of postmenopausal women, one treated with bisphosphonates and the other only with calcium and vitamin D. DESIGN:Retrospective population cohort study with paired matching based on data from electronic health records. SETTING:Women aged 60 years and older in 2005, from 21 primary care centers in a healthcare region of Spain. PARTICIPANTS:Two groups of women aged 60 years and older (n = 1208), prescribed either calcium and vitamin D (CalVitD) or bisphosphonates (BIPHOS) with or without calcium and vitamin D, were compared for the end point of first recorded osteoporotic-related fracture, with 5-years follow-up. MAIN OUTCOME MEASURE:Incidence of first fracture: Vertebral fracture, osteoporosis with pathological fracture, fracture of the upper humeral epiphysis, fracture of the lower radial epiphysis, or femur fracture. RESULTS:Estimated 10-year risk of fracture was 11.4% (95% confidence interval: 9.6 to 13.2), 11.8% (9.2 to 14.3) in the BIPHOS group and 11.1% (8.6 to 13.6) in the CalVitD group. No significant differences were found between groups in total fractures (Hazard ratio = 0.934 (0.67 to 1.31)) or location (vertebral, femoral, radial or humeral). CONCLUSIONS:In postmenopausal women, bisphosphonates have not been shown to better decrease risk of first fracture compared with calcium and vitamin D therapy alone.http://europepmc.org/articles/PMC4393307?pdf=render |
| spellingShingle | Jordi Real Gisela Galindo Leonardo Galván María Antonia Lafarga María Dolors Rodrigo Marta Ortega Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. PLoS ONE |
| title | Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. |
| title_full | Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. |
| title_fullStr | Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. |
| title_full_unstemmed | Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. |
| title_short | Use of oral bisphosphonates in primary prevention of fractures in postmenopausal women: a population-based cohort study. |
| title_sort | use of oral bisphosphonates in primary prevention of fractures in postmenopausal women a population based cohort study |
| url | http://europepmc.org/articles/PMC4393307?pdf=render |
| work_keys_str_mv | AT jordireal useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy AT giselagalindo useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy AT leonardogalvan useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy AT mariaantonialafarga useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy AT mariadolorsrodrigo useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy AT martaortega useoforalbisphosphonatesinprimarypreventionoffracturesinpostmenopausalwomenapopulationbasedcohortstudy |